AUTHORS
Shu Yan, Juan Wu2, Jun Yang3, Yan Liu4, Yujing Zhang5, Juan Chen6, Shujun Tao7, Jing Long8, Peihua (Peggy) Lu, MD9
AFFILIATIONS
1 Hebei Yanda Lu Daopei Hospital, Langfang, China
2 Langfang Blood Center, Langfang, China
3 Langfang Blood Center, Langfang, China
4 Langfang Children's Hospital, Langfang, China
5 The 93437 Unit of the Chinese People's Liberation Army, Baoding, China
6 Hebei Yanda Lu Daopei Hospital, Langfang, China
7 Langfang Blood Center, Langfang, China
8 Hebei Yanda Lu Daopei Hospital, Langfang, China
9 Hebei Yanda Lu Daopei Hospital, Langfang, China
ABSTRACT
Background
Granulocyte transfusion (GT) remains an adjunctive treatment for severe infections in patients with profound neutropenia, yet prospective evidence supporting contemporary GT practice remains limited. We therefore conducted a prospective study evaluating the efficacy, safety, hematologic recovery, donor mobilization, and determinants of treatment response following GT.
Methods
In this single-center prospective study, consecutive patients (pts) with hematologic diseases, neutropenia (ANC <0.5×10?/L), and severe bacterial and/or fungal infections who received GT between April 2023 and March 2025 were included. The study was approved by the Institutional Ethics Committee of Hebei Yanda Lu Daopei Hospital (DPEC-K-202202).Granulocyte products were collected from G-CSF/dexamethasone–mobilized healthy donors using the COBE Spectra mononuclear cell (MNC) apheresis program. The primary endpoints was definitive clinical response (DCR), defined as sustained improvement or resolution of infection based on clinical, microbiological, and radiologic assessments. Secondary endpoints included neutrophil recovery, defervescence, mortality, donor mobilization efficacy, and adverse events (AEs) in both recipients and donors. Repeated GT episodes were analyzed using generalized estimating equations.
Results
The final analysis included 91 pts receiving 214 GT episodes (median, 2 transfusions per patient; range, 1–9). The median age was 29 years, 70.3% were male, and 51.6% had acute myeloid leukemia. 24.2% had a history of allo-HSCT, 65.9% occurred following chemotherapy. Infection types included bacterial (n=35), fungal (n=24), and mixed bacterial/fungal (n=32).
Among 91 pts, 61 (67.0%) achieved DCR and 72 (78.9%) achieved final defervescence within 7 days after transfusion, while 30-day all-cause mortality was 7.7% (7/91). Clinical response varied significantly according to infection type, with DCR rates of 80.0%, 68.8%, and 41.7% in bacterial, mixed bacterial/fungal, and fungal infections, respectively (P=0.009). Multivariable logistic regression identified infection type as the only independent predictor of DCR; compared with fungal infection, bacterial infection (OR, 5.49; 95% CI, 1.74–18.91; P=0.005) and mixed infection (OR, 3.31; 95% CI, 1.08–10.73; P=0.039) were associated with higher response rates. Other clinical factors, including number of GT episodes, history of allo-HSCT, and causes of neutropenia were not associated with DCR.
GT resulted in rapid hematologic recovery, with a mean post-transfusion ANC increase of 1.29×10?/L (P<0.001). Importantly, GT dose demonstrated a dose-response relationship with neutrophil recovery (rmcorr r=0.467, P<0.001), and remained an independent predictor of post-transfusion ANC recovery in GEE analysis (β=0.033 per ×10¹° granulocytes transfused, P<0.001).
Granulocyte products were collected from 184 healthy donors during 213 mobilization procedures. G-CSF plus dexamethasone achieved robust donor mobilization, increasing median WBC from 6.51 to 35.0×10?/L and median ANC from 3.87 to 33.0×10?/L (both P<0.001). Leukapheresis performed 12–18 hours after mobilization yielded significantly higher post-mobilization WBC and ANC levels and greater granulocyte collection efficiency than collection at 6–8 hours (all P<0.05), without increasing processed blood or collection volumes.
GT was well tolerated by both recipients and donors. Only one recipient (1.1%) developed transfusion-related acute lung injury, which resolved with supportive treatment. 28 donors (13.6% per mobilization) occurred AEs, all of which were CTCAE grade 1 and transient. No grade ≥2 donor-related adverse events or other serious donor without serious complications.
Conclusions
Granulocyte transfusion achieved rapid neutrophil recovery, clinically meaningful responses, and favorable safety in neutropenic patients with severe infections. Infection type and granulocyte dose emerged as key determinants of clinical response and hematologic recovery, respectively, supporting individualized GT strateg.
DISCLOSURES
Shu Yan: No relevant conflicts of interest to declare.